: Regorafenib was the first drug to demonstrate a survival benefit as a second-line agent after sorafenib failure in patients with unresectable hepatocellular carcinoma (HCC). Recent studies have shown that its mechanism of action is not only limited to its very broad spectrum of inhibition of angiogenesis, tumor proliferation, spread, and metastasis, but also to its immunomodulatory properties that have favorable effects on the very intricate role that the tumor microenvironment plays in carcinogenesis and tumor growth. In this review, we discuss rationale and evidence supporting regorafenib efficacy in HCC and that led to its approval as a second-line treatment, after sorafenib failure. We also discuss the evidence from clinical practice studies that confirm the results previously achieved in clinical trials. Finally, we analyze the potential role of regorafenib in emerging combined treatment approach with immunotherapy strategies using immune checkpoint blockade and its potential extension to patient categories not included in the registrative study.

Granito, A., Marinelli, S., Forgione, A., Renzulli, M., Benevento, F., Piscaglia, F., et al. (2021). Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC. JOURNAL OF HEPATOCELLULAR CARCINOMA, 8, 477-492 [10.2147/JHC.S251729].

Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC

Granito, Alessandro
Primo
;
Marinelli, Sara
Secondo
;
Forgione, Antonella;Renzulli, Matteo;Benevento, Francesca;Piscaglia, Fabio
Penultimo
;
Tovoli, Francesco
Ultimo
2021

Abstract

: Regorafenib was the first drug to demonstrate a survival benefit as a second-line agent after sorafenib failure in patients with unresectable hepatocellular carcinoma (HCC). Recent studies have shown that its mechanism of action is not only limited to its very broad spectrum of inhibition of angiogenesis, tumor proliferation, spread, and metastasis, but also to its immunomodulatory properties that have favorable effects on the very intricate role that the tumor microenvironment plays in carcinogenesis and tumor growth. In this review, we discuss rationale and evidence supporting regorafenib efficacy in HCC and that led to its approval as a second-line treatment, after sorafenib failure. We also discuss the evidence from clinical practice studies that confirm the results previously achieved in clinical trials. Finally, we analyze the potential role of regorafenib in emerging combined treatment approach with immunotherapy strategies using immune checkpoint blockade and its potential extension to patient categories not included in the registrative study.
2021
Granito, A., Marinelli, S., Forgione, A., Renzulli, M., Benevento, F., Piscaglia, F., et al. (2021). Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC. JOURNAL OF HEPATOCELLULAR CARCINOMA, 8, 477-492 [10.2147/JHC.S251729].
Granito, Alessandro; Marinelli, Sara; Forgione, Antonella; Renzulli, Matteo; Benevento, Francesca; Piscaglia, Fabio; Tovoli, Francesco
File in questo prodotto:
File Dimensione Formato  
JHC-251729-regorafenib-combined-with-other-systemic-therapies--explorin.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale (CCBYNC)
Dimensione 1.61 MB
Formato Adobe PDF
1.61 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/900672
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 21
social impact